NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)
Brief: Cingulate Receives Complete Response Letter From FDA For CTx-1301
US FDA declines to approve Cingulate's ADHD drug
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Cingulate Q1 net loss widens more than expected on commercial preparations
ADHD drug developer Cingulate's Q4 net loss misses analyst expectations as G&A costs rise
Brief: Cingulate Enters Securities Purchase Agreement For Private Placement Includes 2.14 Million Common Shares And 973 Preferred Shares
Brief: Cingulate Inc Files For Mixed Shelf Offering Of Up To $200 Million- SEC Filing
Brief: Shane Schaffer Reinstated As CEO Of Cingulate
Biopharma firm Cingulate's Q3 net loss widens, misses analyst expectations
Brief: Cingulate Presents Positive Phase 3 Results for CTx-1301
Brief: Cingulate Partners With Bend Bio To Manufacture Next-Gen ADHD Treatment, Advancing Commercial Readiness
Brief: Cingulate- On Aug 7, Employment Of Laurie A. Myers As Executive VP & COO Was Terminated - SEC Filing
Brief: Cingulate Submits New Drug Application To FDA For Lead Adhd Asset CTx-1301
Brief: Cingulate Receives $4.3M Waiver From FDA Ahead Of Imminent Filing For Marketing Approval Of Lead Adhd Asset Ctx-1301
Brief: Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study Of Lead Asset Ctx-1301 For Adhd